Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

• Published in: Molecular neurodegeneration Vol. 18; no. 1; pp. 18 - 12
• Main Authors: Gonzalez-Ortiz, Fernando, Kac, Przemysław R., Brum, Wagner S., Zetterberg, Henrik, Blennow, Kaj, Karikari, Thomas K.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.03.2023; BioMed Central; BMC
• Subjects: Advertising executives; Alzheimer; Alzheimer Disease - diagnosis; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Autopsy; Biomarkers; Biomarkers - cerebrospinal fluid; Blood biomarker; Cerebrospinal fluid; Clinical trials; Cognitive ability; Cognitive Dysfunction; Dementia; Dementia disorders; Diagnosis; Diagnostic imaging; Humans; Neurodegeneration; Neurodegenerative diseases; Neuroimaging; Neuropathology; Neurosciences; Neurovetenskaper; Pathology; Phosphorylated tau; Plasma p-tau; Review; s disease; Standardization; Tau protein; tau Proteins - cerebrospinal fluid; Phosphorylated tau; s disease; Plasma p-tau; Alzheimer; Blood biomarker; Dementia

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging biomarkers that concord with neuropathological evidence...